About PharmaCann
PharmaCann is a private company based in Chicago, Illinois. It has reported $508,407,765 raised in 18 offerings on Form D since October 2014.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 7, 2023 | Apr 9, 2024 | $5,000,000fully sold | 3 | $1.6M | Debt, OptionsRule 506(b) | Form D ↗ |
| Nov 6, 2023 | Apr 9, 2024 | $10,000,000fully sold | 1 | $10.0M | Debt, OptionsRule 506(b) | Form D ↗ |
| May 14, 2020 | Apr 9, 2024 | $27,733,613fully sold | 1 | $27.7M | Debt, OptionsRule 506(b) | Form D ↗ |
| Mar 28, 2024 | Apr 9, 2024 | $35,000,000of $50.0M target | 7 | $5.0M | Equity, Debt, OptionsRule 506(b) | Form D ↗ |
| Dec 1, 2023 | Apr 9, 2024 | $10,000,000fully sold | 1 | $10.0M | Debt, OptionsRule 506(b) | Form D ↗ |
| Apr 27, 2023 | Apr 9, 2024 | $7,000,000fully sold | 1 | $7.0M | Debt, OptionsRule 506(b) | Form D ↗ |
| Apr 3, 2023 | Apr 5, 2023amended Apr 9, 2024 | $12,911,111of $18.0M target | 6 | $2.1M | Debt, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 31, 2022 | Nov 7, 2022 | $2,200,000of $25.0M target | 11 | $200K | Convertible Debt SecuritiesRule 506(b) | Form D ↗ |
| Jun 30, 2022 | Jul 8, 2022 | $25,000,000fully sold | 3 | $8.3M | DebtRule 506(b) | Form D ↗ |
| Jun 24, 2021 | Jul 9, 2021 | $85,000,000fully sold | 9 | $9.4M | DebtRule 506(b) | Form D ↗ |
| Jun 14, 2021 | Jun 25, 2021 | $110,392,371fully sold | 1 | $110.3M | OptionsRule 506(b) | Form D ↗ |
| Mar 5, 2021 | Mar 19, 2021 | $31,854,776of $33.0M target | 2 | $15.9M | EquityRule 506(b) | Form D ↗ |
| Sep 10, 2020 | Sep 23, 2020amended Nov 13, 2020 | $35,941,298fully sold | 134 | $268K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 2, 2020 | May 11, 2020 | $19,623,652of $25.0M target | 75 | $261K | EquityRule 506(b) | Form D ↗ |
| Jun 15, 2018 | Jul 2, 2018 | $21,968,435of $30.9M target | 22 | $998K | EquityRule 506(b) | Form D ↗ |
| May 9, 2016 | Jan 23, 2017 | $23,782,436fully sold | 6 | $3.9M | DebtRule 506(b) | Form D ↗ |
| Jun 1, 2015 | Dec 28, 2015 | $25,000,073fully sold | 6 | $4.1M | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 18, 2014 | Oct 3, 2014 | $20,000,000fully sold | 1 | $20.0M | EquityRule 506(b) | Form D ↗ |
| Total, 18 offerings | $508,407,765 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on PharmaCann's Form D filed Apr 9, 2024.
Earlier filings also listed David Chiovetti (executive officer, last listed Nov 2022), Daniel Roth (executive officer, last listed Nov 2022), Patrick Barry (director, last listed Mar 2021), Greg Cappelli (director, last listed Mar 2021), Teddy Scott (ceo and and director, last listed Jul 2018), Norah Scott (executive officer, director and promoter, last listed Dec 2015), John Leja (executive officer and promoter, last listed Dec 2015) and Christina Leja (executive officer, director and promoter, last listed Dec 2015).